SG Americas Securities LLC Buys 6,926 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

SG Americas Securities LLC boosted its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 26.5% in the third quarter, HoldingsChannel reports. The firm owned 33,019 shares of the company’s stock after acquiring an additional 6,926 shares during the period. SG Americas Securities LLC’s holdings in Fulcrum Therapeutics were worth $118,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Fulcrum Therapeutics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company’s stock worth $23,965,000 after purchasing an additional 18,681 shares during the period. Dimensional Fund Advisors LP grew its position in Fulcrum Therapeutics by 13.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company’s stock worth $9,182,000 after purchasing an additional 176,114 shares during the period. Jane Street Group LLC grew its position in Fulcrum Therapeutics by 54.3% in the 1st quarter. Jane Street Group LLC now owns 535,062 shares of the company’s stock worth $5,051,000 after purchasing an additional 188,212 shares during the period. Assenagon Asset Management S.A. bought a new stake in Fulcrum Therapeutics in the 2nd quarter worth approximately $3,084,000. Finally, StemPoint Capital LP grew its position in Fulcrum Therapeutics by 8.1% in the 1st quarter. StemPoint Capital LP now owns 407,108 shares of the company’s stock worth $3,843,000 after purchasing an additional 30,535 shares during the period. Institutional investors own 89.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on FULC. HC Wainwright downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $17.00 to $4.00 in a research report on Friday, September 13th. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. Royal Bank of Canada downgraded shares of Fulcrum Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $15.00 to $4.00 in a research report on Thursday, September 12th. Bank of America downgraded shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and cut their price objective for the company from $10.00 to $2.00 in a research report on Thursday, September 12th. Finally, Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.33.

Fulcrum Therapeutics Stock Performance

FULC opened at $3.19 on Friday. Fulcrum Therapeutics, Inc. has a fifty-two week low of $2.87 and a fifty-two week high of $13.70. The firm’s fifty day moving average is $5.41 and its 200 day moving average is $6.89. The stock has a market cap of $199.06 million, a price-to-earnings ratio of -9.11 and a beta of 2.21.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Wednesday, July 31st. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.93. The firm had revenue of $80.00 million for the quarter, compared to analysts’ expectations of $80.00 million. During the same quarter last year, the firm posted ($0.38) EPS. On average, equities research analysts predict that Fulcrum Therapeutics, Inc. will post -0.28 earnings per share for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.